SurModics (SRDX) Tops Q2 EPS by 15c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Forward Air (FWRD) Appoints Shawn Stewart as CEO
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Surmodics Reports Second Quarter Fiscal 2020 Results and Provides COVID-19 Pandemic Update
April 29, 2020 4:05 PM EDTEDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2020 second quarter ended March 31, 2020, and suspended its financial guidance for fiscal 2020.
Summary of Second Quarter and Recent Highlights
Revenue of $22.8 million, an increase of 1% year-over-year GAAP EPS of $0.11, non-GAAP EPS of $0.04 Cash and short-term investments of $48.4 million CE Mark clearance received for Telemark coronary/peripheral support microcatheter Partnership announced with Cook Medical for... More
